Literature DB >> 18334597

Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening.

Franck Madoux1, Xiaolin Li, Peter Chase, Gina Zastrow, Michael D Cameron, Juliana J Conkright, Patrick R Griffin, Scott Thacher, Peter Hodder.   

Abstract

The steroidogenic factor 1 (SF-1, also known as NR5A1) is a transcription factor belonging to the nuclear receptor superfamily. Whereas most of the members of this family have been extensively characterized, the therapeutic potential and pharmacology of SF-1 still remains elusive. Described here is the identification and characterization of selective inhibitory chemical probes of SF-1 by a rational ultra-high-throughput screening (uHTS) strategy. A set of 64,908 compounds from the National Institute of Health's Molecular Libraries Small Molecule Repository was screened in a transactivation cell-based assay employing a chimeric SF-1 construct. Two analogous isoquinolinones, ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-7-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate (SID7969543) and ethyl 2-[2-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate and (SID7970631), were identified as potent submicromolar inhibitors, yielding IC(50) values of 760 and 260 nM. The compounds retained their potency in a more physiologic functional assay employing the full-length SF-1 protein and its native response element, yielding IC(50) values of 30 and 16 nM, respectively. The selectivity of these isoquinolinones was confirmed via transactivation-based functional assays for RAR-related orphan receptor A (RORA), Herpes simplex virus transcriptional activator protein Vmw65 (VP16), and liver receptor homolog 1 (LRH-1). Their cytotoxicity, solubility, permeability and metabolic stability were also measured. These isoquinolinones represent valuable chemical probes to investigate the therapeutic potential of SF-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334597      PMCID: PMC3228235          DOI: 10.1124/mol.108.045963

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Binding of ligands and activation of transcription by nuclear receptors.

Authors:  A C Steinmetz; J P Renaud; D Moras
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

3.  Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner.

Authors:  Yoon-Kwang Lee; David D Moore
Journal:  J Biol Chem       Date:  2001-10-19       Impact factor: 5.157

4.  GAL4-VP16 is an unusually potent transcriptional activator.

Authors:  I Sadowski; J Ma; S Triezenberg; M Ptashne
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

5.  25-Hydroxycholesterol is not a ligand for the orphan nuclear receptor steroidogenic factor-1 (SF-1).

Authors:  S H Mellon; S R Bair
Journal:  Endocrinology       Date:  1998-06       Impact factor: 4.736

6.  Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity.

Authors:  Gregor Majdic; Morag Young; Elise Gomez-Sanchez; Paul Anderson; Lidia S Szczepaniak; Robert L Dobbins; J Denis McGarry; Keith L Parker
Journal:  Endocrinology       Date:  2002-02       Impact factor: 4.736

Review 7.  Steroidogenic factor 1: an essential mediator of endocrine development.

Authors:  Keith L Parker; Douglas A Rice; Deepak S Lala; Yayoi Ikeda; Xunrong Luo; Margaret Wong; Marit Bakke; Liping Zhao; Claudia Frigeri; Neil A Hanley; Nancy Stallings; Bernard P Schimmer
Journal:  Recent Prog Horm Res       Date:  2002

8.  Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids.

Authors:  Y Sadovsky; P A Crawford; K G Woodson; J A Polish; M A Clements; L M Tourtellotte; K Simburger; J Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes.

Authors:  Andria L Del Tredici; Carsten B Andersen; Erika A Currier; Steven R Ohrmund; Luke C Fairbain; Birgitte W Lund; Norman Nash; Roger Olsson; Fabrice Piu
Journal:  Mol Pharmacol       Date:  2007-11-30       Impact factor: 4.436

10.  SF-1 a key player in the development and differentiation of steroidogenic tissues.

Authors:  Pierre Val; Anne-Marie Lefrançois-Martinez; Georges Veyssière; Antoine Martinez
Journal:  Nucl Recept       Date:  2003-09-18
View more
  27 in total

1.  Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.

Authors:  Joshua Roth; Franck Madoux; Peter Hodder; William R Roush
Journal:  Bioorg Med Chem Lett       Date:  2008-03-14       Impact factor: 2.823

2.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

3.  Small-molecule inhibitors of bacterial AddAB and RecBCD helicase-nuclease DNA repair enzymes.

Authors:  Susan K Amundsen; Timothy Spicer; Ahmet C Karabulut; Luz Marina Londoño; Christina Eberhart; Virneliz Fernandez Vega; Thomas D Bannister; Peter Hodder; Gerald R Smith
Journal:  ACS Chem Biol       Date:  2012-03-23       Impact factor: 5.100

4.  Bioluminescence methodology for the detection of protein-protein interactions within the voltage-gated sodium channel macromolecular complex.

Authors:  Alexander Shavkunov; Neli Panova; Anesh Prasai; Ron Veselenak; Nigel Bourne; Svetla Stoilova-McPhie; Fernanda Laezza
Journal:  Assay Drug Dev Technol       Date:  2012-02-24       Impact factor: 1.738

5.  In pursuit of synthetic modulators for the orphan retina-specific nuclear receptor NR2E3.

Authors:  Qiong Qin; Anna Knapinska; Nicoleta Dobri; Franck Madoux; Peter Chase; Peter Hodder; Konstantin Petrukhin
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-25       Impact factor: 2.671

Review 6.  The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis.

Authors:  Sang Jun Han; Bert W O'Malley
Journal:  Hum Reprod Update       Date:  2014-03-14       Impact factor: 15.610

7.  Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening.

Authors:  Timothy Spicer; Virneliz Fernandez-Vega; Peter Chase; Louis Scampavia; Joyce To; John P Dalton; Fabio L Da Silva; Tina S Skinner-Adams; Donald L Gardiner; Katharine R Trenholme; Christopher L Brown; Partha Ghosh; Patrick Porubsky; Jenna L Wang; David A Whipple; Frank J Schoenen; Peter Hodder
Journal:  J Biomol Screen       Date:  2014-03-11

8.  Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation: DRUGGABILITY OF THE SMALL GTPase Rab27a.

Authors:  Jennifer L Johnson; Mahalakshmi Ramadass; Jing He; Steven J Brown; Jinzhong Zhang; Lusine Abgaryan; Nikolaos Biris; Evripidis Gavathiotis; Hugh Rosen; Sergio D Catz
Journal:  J Biol Chem       Date:  2016-10-04       Impact factor: 5.157

9.  Endometrial Expression of Steroidogenic Factor 1 Promotes Cystic Glandular Morphogenesis.

Authors:  Yasmin M Vasquez; San-Pin Wu; Matthew L Anderson; Shannon M Hawkins; Chad J Creighton; Madhumita Ray; Sophia Y Tsai; Ming-Jer Tsai; John P Lydon; Francesco J DeMayo
Journal:  Mol Endocrinol       Date:  2016-03-28

Review 10.  Phospholipid--driven gene regulation.

Authors:  Paul M Musille; Jeffrey A Kohn; Eric A Ortlund
Journal:  FEBS Lett       Date:  2013-01-16       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.